Inhibition of CXCR2 in vivo also reduced NETs formation and DLBCL progression, just as TLR9 inhibition inhibited growth and lymph node metastasis in DLBCL patients (53). The gene discussed is TLR9; the disease is diffuse large B-cell lymphoma.